Shreeram Aradhye

Money Moves

As of September 2026: Overseeing clinical development after multiple setbacks

Novartis' experimental muscle-disease drug del-desiran failed its phase 3 Harbor trial, missing the primary endpoint and sending shares down. The drug was the centerpiece of the company's $12 billion acquisition of Avidity Biosciences, which closed last year.

Updated Sep 8